Relmada Therapeutics (RLMD) is back in focus after releasing 12 month interim Phase 2 data for NDV-01 in high risk non muscle invasive bladder cancer, alongside a roughly US$160 million oversubscribed ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果